STATEMENT OF INDEPENDENCE
As a provider of CME accredited by the Accreditation Council for Continuing Medical Education, the Endocrine Society has a policy of ensuring that the content and quality of this educational activity are balanced, independent, objective, and scientifically rigorous. The scientific content of this activity was developed under the supervision of the Endocrine Society’s Clinical Endocrinology Update Steering Committee.


DISCLOSURE POLICY
The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.


CLINICAL ENDOCRINOLOGY UPDATE STEERING COMMITTEE

The following steering committee members reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Daniel Bessesen, MD has served on the Safety Monitoring Committee for Enteromedics, Inc; and has received grant support from the National Institutes of Health. 

Sigridur Bjornsdottir, MD, PhD has served on an advisory group for Amgen; has received research support from Shire; and has been a speaker for Mylan and Shire. 

Marc-Andre Cornier, MD has received grant funding from the National Institutes of Health, the Department of Veterans Affairs, and Regeneron. 

Monica Gadelha, MD, PhD has served on an advisory board for Novartis; has served as a lecturer for Novartis, Ipsen, and Pfizer; has received an unrestricted research grant from Ipsen; has served as primary investigator of clinical trials for Novartis and Ipsen; and has been employed by Instituto Estadual do Cerebro Paulo Niemeyer. 

Whitney Goldner, MD has served as primary investigator for Eisai (phase 3 trial) and Roche; and has served as a member of the NCCN thyroid cancer guidelines panel and adrenal tumor/neuroendocrine tumor guidelines panel; and has served on the Trainee and Early Career Development Committee, Awards Committee and Thyroid Cancer Guidelines committee for American Thyroid Association.

Tim Korevaar, MD, PhD has received speaker fees from Goodlife Healthcare B.V., Berlin Chemie, and Quidel. 

Connie Baum Newman, MD has served as a member of the National Lipid Association's Graduate Medical Education Committee and American Heart Association's Clinical Lipidology Committee; has served as the past president of the American Medical Women's Association; and has served on the Food and Drug Administration's Endocrinologic and Metabolic Diseases Advisory Committee. 

Camille Powe, MD has received salary support and grant funding from the NIH National Institute of Diabetes and Digestives and Kidney Diseases (K23) and the Robert Wood Johnson Foundation's Harold Amos Faculty Development Program; has served as section editor for Current Diabetes Reports; and has participated in the NIH Clinical Research Loan Repayment Program.  

Micol Rothman, MD has served on the Professional Practice Committee of the American Society for Bone and Mineral Research.

The following faculty report no relevant financial relationships: Richard Bebb, MD; Serena Cardillo, MD


PRESENTING FACULTY

The following presenting faculty reported the following relevant financial relationship(s) that they or their spouse/partner have with commercial interests:

Anders Carlson, MD has had his institution receive remuneration for consulting and/or clinical research from Novo Nordisk, Sanofi, Medtronic, Dexcom, Abbott, Eli Lilly, and Insulet. 

Adi Cohen, MD has received research support from Eli Lilly and Amgen. 

Maria Fleseriu, MD has received scientific consulting fees from Novarits and Strongbridge; and has had her institution receive research support from Novartis, Millendo, and Strongbridge

George J. Kahaly, MD, PhD has served as a consultant to Quidel USA; and has had his institution receive a research grant from Quidel. 

E. Micheal Lewiecki, MD has had his employer receive research grants from Radius, Amgen, Mereo, and Bindex; has received income for service on scientific advisory board or consulting from AMgen, Radius, Alexion, Sandoz, Samsung, and Bioepis; has served on speakers bureaus for Radius, Alexion; has worked on project development for University of New Mexico; has received royalties from UpToDate sections; and has served as a board member for the National Osteoporosis Foundation, International Society for Clinical Densitometry, and Osteoporosis Foundation of New Mexico. 

Mark E. Molitch, MD has served as a consultant to Merck, Pfizer, Novartis, Chiasma, Corcept and Janssen; and has worked as a primary investigator for Janssen, Novartis, and Bayer. 

David M. Nathan, MD has received research support from Alere, Inc (now Abbott). 

Mary-Elizabeth Patti, MD has served as a collaborator for NIH R44 grant funded by Xeris Pharmaceuticals; has worked as a consultant for Fractyl and Eiger Pharmaceuticals; and has received investigator-initiated research support to her institution from Xeris Pharmaceuticals and Dexcom.

Micol Rothman, MD has served on the Professional Practice Committee of the American Society for Bone and Mineral Research.

Donna H. Ryan, MD has received consulting fees from Amgen, Bausch Health, Boeringer Ingelheim, Gila Therapeutics, IFA Celtic, Janssen, KVK Tech, Novo Nordisk, Phenomix, Quintiles, Real Appeal (United Health), ReDesign Health, Sanofi, and Scientific Intake; has served on the speakers bureau for Novo Nordisk; has an ownership interest in Gila Therapeutics, Phenomix, Xeno Bioscience, Epitomee, ReDesign Health and Scientific Intake; and has served on the SELECT Steering Committee for Novo Nordisk. 

Joseph G. Verbalis, MD has received consulting fees from Ferring Pharmaceuticals; and has received research support from Corcept Therapeutics. 

Nelson B. Watts, MD has served as a consultant for Abbvie, Amgen, and Sanofi; and served as a speaker for Amgen and Radius. 

Carol Wysham, MD has served as a consultant to Astra Zeneca, Abbott, Janssen, Novo Nordisk, and Sanaofi; has been in the speakers bureau for Astra Zeneca, Boehringer Ingelheim, Janssen, Novo Nordisk, and Sanofi; and has received research funding from Abbott, Novo Nordisk and Mylan. 

The following faculty report no relevant financial relationships: Shehzad S. Basaria, MD; Anuja Dokras, MD, PhD; Stephanie Fish, MD; Scott Kahan, MD, MPH; Carol J. Levy, MD, CDE; Shlomo Melmed, MD; Lynnette K. Nieman, MD;  Elizabeth N. Pearce, MD, MSc; Matthew D. Ringel, MD; Robert C. Stanton, MD; Lisa R. Tannock, MD; Anand Vaidya, MD, MMSc; Margaret E. Wierman, MD; William F. Young, Jr, MD, MSc.

Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.


DISCLAIMERS
The information presented in this activity represents the opinion of the faculty and is not necessarily the official position of the Endocrine Society.

USE OF PROFESSIONAL JUDGMENT:
The educational content in this self-assessment test relates to basic principles of diagnosis and therapy and does not substitute for individual patient assessment based on the health care provider’s examination of the patient and consideration of laboratory data and other factors unique to the patient. Standards in medicine change as new data become available.

DRUGS AND DOSAGES:
When prescribing medications, the physician is advised to check the product information sheet accompanying each drug to verify conditions of use and to identify any changes in drug dosage schedule or contraindications.
 

POLICY ON UNLABELED/OFF-LABEL USE
The Endocrine Society has determined that disclosure of unlabeled/off-label or investigational use of commercial product(s) is informative for audiences and therefore requires this information to be disclosed to the learners at the beginning of the presentation. Uses of specific therapeutic agents, devices, and other products discussed in this educational activity may not be the same as those indicated in product labeling approved by the Food and Drug Administration (FDA). The Endocrine Society requires that any discussions of such “off-label” use be based on scientific research that conforms to generally accepted standards of experimental design, data collection, and data analysis. Before recommending or prescribing any therapeutic agent or device, learners should review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse events.


PRIVACY AND CONFIDENTIALITY STATEMENT
The Endocrine Society will record learner’s personal information as provided on CME evaluations to allow for issuance and tracking of CME certificates. The Endocrine Society may also track aggregate responses to questions in activities and evaluations and use these data to inform the ongoing evaluation and improvement of its CME program. No individual performance data or any other personal information collected from evaluations will be shared with third parties.


ACKNOWLEDGMENT OF COMMERCIAL SUPPORT
This activity is supported by independent educational grants from Corcept Therapeutics, Exelixis, Lilly USA, Merck & Co., Strongbridge Biopharma, and Xeris Pharmaceuticals.